AM-Pharma is a clinical-stage biopharmaceutical company developing a treatment for sepsis-associated acute kidney injury (SA-AKI) – recombinant human alkaline phosphatase therapeutic. The company is focused on the successful execution of its Phase III REVIVAL pivotal trial while continuing to build an organization committed to using its insight and knowledge for other severe medical conditions, including …